Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and
pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin,
for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or
metastatic non squamous non-small cell lung cancer (NSCLC).